High-dose clopidogrel loading in percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.
• Antiplatelet therapy is crucial to prevent thrombotic complications after PCI.
• Clopidogrel is a widely used P2Y12 inhibitor for antiplatelet therapy.

Purpose of the Study:

• To review the clinical use and evidence supporting a 600-mg clopidogrel loading dose in patients undergoing PCI.
• To compare the efficacy and safety of a 600-mg loading dose versus a 300-mg loading dose of clopidogrel.

Main Methods:

• Literature search of PubMed (1966-March 2005), bibliographies, and manufacturer data.
• Inclusion of human clinical trials and platelet function studies.
• Analysis of available randomized controlled trials and observational data.

Main Results:

• A 600-mg clopidogrel loading dose achieves maximum platelet inhibition within 2 hours, compared to over 6 hours with a 300-mg dose.
• Multiple studies have investigated the 600-mg dose, with one randomized trial directly comparing it to the 300-mg dose.
• The 600-mg loading dose demonstrated greater effectiveness in reducing periprocedural events and similar safety in lower-risk patients.

Conclusions:

• Pretreatment with a 600-mg clopidogrel loading dose is more effective than 300 mg for reducing periprocedural events in lower-risk patients undergoing PCI, with comparable safety.
• Further research is necessary to establish optimal use in higher-risk patients, with concurrent glycoprotein IIb/IIIa receptor antagonism, or when dosing is delayed.